Petros Other Liab vs Common Stock Total Equity Analysis
| PTPI Stock | USD 0.27 0.01 3.85% |
Petros Pharmaceuticals financial indicator trend analysis is much more than just breaking down Petros Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Petros Pharmaceuticals is a good investment. Please check the relationship between Petros Pharmaceuticals Other Liab and its Common Stock Total Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.
Other Liab vs Common Stock Total Equity
Other Liab vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Petros Pharmaceuticals Other Liab account and Common Stock Total Equity. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Petros Pharmaceuticals' Other Liab and Common Stock Total Equity is -0.07. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Petros Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Petros Pharmaceuticals' Other Liab and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Petros Pharmaceuticals are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Other Liab i.e., Petros Pharmaceuticals' Other Liab and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | -0.07 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Liab
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Petros Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Petros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.The Petros Pharmaceuticals' current Selling General Administrative is estimated to increase to about 11.6 M, while Tax Provision is projected to decrease to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.2M | 3.7M | 4.2M | 4.4M | Total Revenue | 7.8M | 6.0M | 5.8M | 7.2M |
Petros Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Petros Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Petros Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 453.1K | 29.1M | 26.4M | 4.0M | 7.8M | 10.7M | |
| Total Current Liabilities | 41.1M | 41.9M | 31.0M | 7.1M | 10.8M | 10.2M | |
| Retained Earnings | (41.1M) | (61.7M) | (70.7M) | (90.7M) | (98.9M) | (93.9M) | |
| Accounts Payable | 3.8M | 5.6M | 4.6M | 1.8M | 1.7M | 2.6M | |
| Net Receivables | 3.8M | 5.2M | 2.5M | 2.1M | 2.2M | 2.6M | |
| Inventory | 2.2M | 760.5K | 519.6K | 1.8M | 1.6M | 1.8M | |
| Other Current Assets | 1.9M | 2.9M | 3.1M | 1.3M | 3.2M | 2.6M | |
| Total Current Assets | 12.1M | 25.9M | 30.5M | 14.7M | 20.4M | 21.9M | |
| Common Stock | 29.1M | 971.0 | 2.1K | 208.0 | 298.0 | 283.1 |
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Petros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.